跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 382 条关于
“Waldenstrom Macroglobulinemia”
全部
382
临床试验
334
药物
1
机构
0
资讯
47
去年
ImmunityBio's CD19 CAR-NK Therapy Achieves Complete Responses in Late-Stage Waldenstrom Macroglobulinemia
2年前
BeiGene's BGB-16673 Shows Promise in Blood Cancer Treatment with Projected $9M Revenue by 2037
去年
CAR-T Therapies AT-19 and XYF-19 Show Promise in Treating B-Cell Lymphomas
去年
ImmunityBio's ANKTIVA Shows Promise in Reversing Lymphopenia in Advanced Lung Cancer Patients
7个月前
FDA Accepts Tirabrutinib NDA for Rare Brain Lymphoma Under Accelerated Approval Pathway
去年
Iopofosine I 131 Shows Promise in Heavily Pretreated Waldenström Macroglobulinemia
5年前
FDA Approves Zanubrutinib for Waldenström's Macroglobulinemia Treatment
去年
Schrödinger's SGR-1505 Receives FDA Fast Track Designation for Relapsed Waldenström Macroglobulinemia
2年前
Iopofosine I-131 Demonstrates Promising Results in Relapsed/Refractory Waldenström Macroglobulinemia
去年
Breakthrough Developments in Waldenström Macroglobulinemia Treatment: BTK Inhibitors and Novel Therapies Show Promise
第 1 页，共 5 页
上一页
下一页
